Aviado · Research
Longevity Daily
Tuesday, June 16, 2026
Listen
Today's Brief
Today's standout story is a landmark Nature Medicine study of 60,000+ people showing that different cell types in the same body age at dramatically different rates — and that a blood test may soon reveal which ones are racing ahead. Obesity, it turns out, accelerates brain aging through the exact same molecular pathway as normal cognitive decline, making weight control a direct neuroprotection strategy. Also ahead: new conference data on blocking CD38 to preserve NAD+, a 20-year NIH trial confirming lifestyle beats metformin for multimorbidity prevention, and BioAge's NLRP3 inhibitor entering Phase 2 cardiovascular aging trials.
10 stories2 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Dementia With Lewy Bodies Is More Common and More Underdiagnosed Than We Thought
A new meta-analysis published in JAMA Neurology finds that dementia with Lewy bodies -- the second most common degenerative dementia after Alzheimer's -- rises sharply with age and has been substantially underestimated across existing epidemiological data. This matters because DLB presents with a distinctive mix of cognitive and motor symptoms often confused with Parkinson's disease or Alzheimer's, and treatment approaches differ meaningfully between them. If you or a loved one are experiencing cognitive changes alongside movement difficulties or vivid, disruptive dreams, this data supports pushing for a more specific neurological workup rather than a default Alzheimer's diagnosis.
Read more →Obesity and Normal Brain Aging Share an Identical Molecular Pathway
New research finds that obesity-induced memory loss operates through the exact same biological mechanism as normal age-related cognitive decline -- not a parallel or overlapping process, but the same one. This reframes excess body weight not just as a cardiovascular or metabolic risk, but as a direct accelerant of brain aging. For anyone building a cognitive longevity protocol, this is strong evidence that weight management belongs at the top of the list alongside sleep and aerobic fitness.
Read more →Supplements & Compounds
Blocking the Enzyme That Destroys NAD+ May Be Smarter Than Just Topping It Up
Emerging research presented at a major NAD+ metabolism conference is shifting focus from raising NAD+ levels -- via NMN or NR supplementation -- toward preventing its breakdown, specifically by inhibiting CD38, the enzyme responsible for consuming most of the body's NAD+. Botanical compounds targeting CD38, including apigenin and quercetin, are gaining serious research attention as complements or alternatives to precursor-only approaches. If you're already taking an NAD+ precursor, this science suggests pairing it with a CD38 inhibitor could meaningfully extend the benefits by slowing the drain.
Read more →Aviado Research: Featured Analysis
This week's Aviado Research deep-dive applies rigorous evidence review to one of longevity science's most actively evolving areas, separating the signal from the noise across emerging compounds and mechanisms. As with all Aviado analyses, the focus is on what the evidence actually supports for health-conscious individuals -- not what the supplement industry wants you to believe.
Read the full Aviado analysis →Research & Papers
GLP-1 Drugs Slow Epigenetic Aging -- But the Real Credit Goes to Fat Loss
A new analysis finds that GLP-1 receptor agonists like semaglutide measurably slow epigenetic aging -- but the author argues persuasively that this effect is not a unique drug property; it's a sizable confirmation of the harms done by excess visceral fat and the benefits of losing it. The implication: the same epigenetic aging benefits would likely follow from any comparable method of fat reduction, whether through caloric restriction, bariatric surgery, or dedicated exercise. For longevity-focused GLP-1 users, the drug is working through fat reduction -- making the underlying lifestyle changes equally valid, and potentially more durable, paths to the same outcome.
Read more →Lifestyle & Nutrition
20-Year NIH Trial Confirms: Lifestyle Change Prevents Chronic Disease -- Metformin Doesn't
A landmark NIH-supported clinical trial following adults with prediabetes for more than two decades found that structured lifestyle intervention significantly reduced the risk of developing multiple chronic conditions -- while metformin showed no statistically significant benefit for the same outcome. This directly challenges the narrative that metformin can substitute for lifestyle change in metabolic disease prevention, a common assumption in longevity circles where metformin use is popular. The bottom line for health optimizers: real diet and exercise interventions outperform pharmacology for long-term multimorbidity prevention, reinforcing a lifestyle-first, drugs-second hierarchy.
Read more →The Person You Live With Is Shaping Your Microbiome -- and Your Metabolic Risk
New research finds that household cohabitation -- not shared genetics -- is the primary driver of strain-level microbiome alignment between people who live together, and this microbial sharing extends specifically to bacteria linked to type 2 diabetes risk. The implication is striking: your metabolic health may be meaningfully influenced by the microbial ecosystem of your partner or housemates, entirely independent of DNA. This raises new questions about whether household-level probiotic or dietary interventions could serve as a shared metabolic health strategy -- protecting the whole household, not just individuals.
Read more →The Weekly Resistance Training Sweet Spot for Longevity: 90 to 119 Minutes
New research finds that 90 to 119 minutes of resistance training per week is associated with a 13% lower risk of all-cause mortality and a 19% reduction in heart disease risk. Importantly, more is not necessarily better -- the mortality benefit appears to plateau and may diminish beyond this range. For anyone structuring a longevity-focused fitness routine, this translates to roughly two focused strength sessions per week to hit the sweet spot without overreaching.
Read more →Industry & Policy
BioAge's NLRP3 Inflammasome Inhibitor Enters Phase 2 in Cardiovascular Aging Trial
BioAge Labs has dosed its first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 -- an orally available, brain-penetrant NLRP3 inflammasome inhibitor targeting cardiometabolic disease through the biology of aging. Phase 1 results showed BGE-102 achieved what the company calls potential best-in-class reductions in hsCRP, a key inflammatory biomarker, and was well-tolerated across all dose levels. Topline data is expected in the second half of 2026, making this a trial worth watching closely for anyone tracking the emerging senoinflammation-to-cardiovascular-disease pipeline.
Read more →